Clarivate Plc (NYSE:CLVT) is one of the best affordable stocks under $5 to invest in. On July 18, Jefferies downgraded ...

Fintel reports that on July 18, 2025, Jefferies downgraded their outlook for Clarivate (NYSE:CLVT) from Buy to Hold. Analyst ...

The firm said that while Clarivate’s valuation remains attractive, it now expects revenue in 2026 to be roughly flat compared to 2025, with risks building from potential U.S. government funding cuts ...

This important study uses data on over 56 million articles to examine the dynamics of interdisciplinarity and international collaborations in research journals. The data analytics used to quantify ...

TEHRAN – The fourth nanotechnology summer school will kick off on July 23 and is scheduled to run for two months.

Married researchers have published more than 1,000 peer-reviewed papers and are pioneers of artificial intelligence in ...

6) Lecanemab: Clarivate delivers a vote of confidence in Eisai and Biogen's anti-amyloid antibody lecanemab for Alzheimer's disease – just approved by the FDA as Leqembi – after the debacle of ...

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Find the latest Clarivate Plc (CLVT) stock quote, history, news and other vital information to help you with your stock trading and investing.